Skye Bioscience, Inc.(SKYE)

Biotechnology · San Diego, CA

$1.66-0.07 (-4.05%)

Delayed quote: Oct 6, 2026, 3:08 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T19:13:36.659Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:13:36.659Z.

Quote observation: 2026-10-06T19:08:14.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 7,292,322
Total debt · period ending 2026-06-30: 35,696
Cash · period ending 2026-06-30: 8,068,357
TTM operating income · period ending 2026-06-30: -51,895,747

FMP input reference: 8c4e2329810c85a761ec37603feeca28f75a2d8b2781946fcb814d6340a505d6

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SKYE EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

SKYE Competitors' EV/EBIT Ratio

SKYE

Skye Bioscience, Inc.

Current

Market Cap

$7.29M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LGVN

Longeveron Inc.

vs SKYE

Market Cap

$7.24M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INM

InMed Pharmaceuticals Inc.

vs SKYE

Market Cap

$7.36M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGRX

Mangoceuticals, Inc.

vs SKYE

Market Cap

$7.39M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CURX

Curanex Pharmaceuticals Inc Common Stock

vs SKYE

Market Cap

$7.00M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NRSN

NeuroSense Therapeutics Ltd.

vs SKYE

Market Cap

$7.08M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KALA

KALA BIO, Inc.

vs SKYE

Market Cap

$6.96M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CODX

Co-Diagnostics, Inc.

vs SKYE

Market Cap

$6.94M

EV/EBIT Ratio

N/A

TTM Avg

1.45x

3Y Avg

7.74x

5Y Avg

7.74x

BOLT

Bolt Biotherapeutics, Inc.

vs SKYE

Market Cap

$6.87M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NDRA

ENDRA Life Sciences Inc.

vs SKYE

Market Cap

$7.79M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Skye Bioscience, Inc. (SKYE)	$7.29M	N/A	N/A	N/A	N/A
Longeveron Inc. (LGVN)vs ›	$7.24M	N/A	N/A	N/A	N/A
InMed Pharmaceuticals Inc. (INM)vs ›	$7.36M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$7.39M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.00M	N/A	N/A	N/A	N/A
NeuroSense Therapeutics Ltd. (NRSN)vs ›	$7.08M	N/A	N/A	N/A	N/A
KALA BIO, Inc. (KALA)vs ›	$6.96M	N/A	N/A	N/A	N/A
Co-Diagnostics, Inc. (CODX)vs ›	$6.94M	N/A	1.45x	7.74x	7.74x
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.87M	N/A	N/A	N/A	N/A
ENDRA Life Sciences Inc. (NDRA)vs ›	$7.79M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

SKYE EV/EBIT Ratio Metrics

SKYE Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics